ENGN enGene Holdings Inc.

$1.70

enGene Holdings Inc. (ENGN) is expected to report earnings on September 14, 2026, before the market open. The consensus earnings estimate is a loss of $0.47 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.9% since its last earnings release on June 15, 2026.

enGene Beat Consensus Estimates
Monday, June 15, 2026 · 9:00 AM ET
Earnings Date
3rd Quarter, Jul 2026
Sep 14
Monday · 9:00 AM ET
Earnings Whisper
-
vs ($0.47)
Rev est $52.4M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.81

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About enGene Holdings Inc.

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

Sector

Healthcare

Industry

Biotechnology